This program aims to help clinicians better identify clinical presentation features of atopic dermatitis (AD) warranting a timely and accurate differential diagnosis; recognize patients for whom biologic therapies should be considered as part of treatment plans for the management of moderate-to-severe AD, and coordinate with specialists to provide patient-specific, long-term care for moderate-to-severe AD.

RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026

Welcome to this educational snapshot of type 2 inflammation (T2I), designed to expand the knowledge base of allergists, immunologists, and other clinicians who manage type 2 inflammatory conditions such as atopic dermatitis, COPD, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic esophagitis. In this program, the presenter will discuss the pathophysiology and interrelated pathways of the type 2 inflammatory response and how these may guide biomarker assessment and the selection of biologic therapies for T2I-related diseases. The program will also examine the importance of interdisciplinary care and referral systems in managing patients with multiple comorbid T2I-related diseases.

RELEASED DATE: March 27, 2026
EXPIRATION DATE: March 27, 2027

This innovative online enduring activity is designed to enhance clinicians’ understanding and management of atopic dermatitis (AD). It equips healthcare professionals with the knowledge to recognize the clinical characteristics of AD, highlighting key differences between adults and pediatric presentations. The program also explores the therapeutic benefits of biologics for patients with moderate-to-severe AD. Additionally, it promotes a multidisciplinary team (MDT) approach to improve collaboration across specialties, emphasizing timely dermatology referrals for optimal patient care.

RELEASED DATE: September 30, 2025
EXPIRATION DATE: September 30, 2026

Veterans face a unique and heightened burden from moderate-to-severe asthma, experiencing worsened morbidity and mortality due to the condition. This grand rounds enduring is designed to equip healthcare professionals in the VA setting with practical, evidence-based strategies to improve care for veteran patients with moderate-to-severe asthma. Through interactive, case-based learning, participants will enhance their understanding of type 2 inflammation, gain proficiency in the use of biologic therapies, and learn to individualize treatment plans to their veteran patients’ needs, all with the goal of improving outcomes for veteran patients with moderate-to-severe asthma.

RELEASED DATE: November 21, 2025
EXPIRATION DATE: November 21, 2026

This enduring activity is designed to enhance healthcare professionals’ understanding of the role of type 2 inflammation in asthma’s complex pathology and its impact on disease progression. Participants will explore evidence-based approaches for incorporating biologic therapies into individualized treatment plans and learn strategies for selecting the most appropriate biologic therapy based on patient-specific needs, preferences, and goals to optimize outcomes in moderate-to-severe asthma management. The program will also review GINA recommendations and when to incorporate biologic therapy.

RELEASED DATE: October 30, 2025
EXPIRATION DATE: October 30, 2026

Thursday, May 30, 2024

7:00PM – 8:00PM ET

Please note this Clinical Conversation program is 7:00PM Eastern, 6:00PM Central, 5:00PM Mountain and 4:00PM Pacific.